Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma

摘要: We have studied the clinical effects of a murine monoclonal anti-human T-cell antibody in seven patients with lymphoma. Four to 17 treatments anti-Leu-1 were given each patient over periods 14–75 days. Doses ranged from 250 micrograms 100 mg. Antibody usually caused rapid fall circulating T cells, return baseline levels within 24–48 hr. The optimum dose appeared vary for patient. Clearance tumor cells correlated amount bound cells. Other than dyspnea one patient, no serious toxicity was noted. Five had definite responses, but these short duration (1.5–4 mo). developed anti-mouse immunoglobulin (Ig) antibodies, and three patients, this responsible escape therapy. Although 95% host Ig response directed against mouse constant region determinants, small significant component found be antiidiotype.